Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.

Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Abstract Text:

Margaret Weiss,Lily Hechtman,Atilla Turgay,Umesh Jain,Declan Quinn,Tahira S Ahmed,Timothy Yates,Joseph L Reiz,Graeme A E Donnelly,Zoltan Harsanyi,Andrew C Darke,

Objective: The purpose of this study was to evaluate the comparative efficacy and safety of a novel long-duration multilayer-release (MLR) methylphenidate (MPH) formulation and immediate-release (IR) MPH in attention-deficit/hyperactivity disorder (ADHD) children. Patients and Methods: This study was a randomized, double-blind, crossover comparison of once-daily MLR and twice-daily IR-MPH in home and school settings in children with a Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) diagnosis of ADHD. Patients completed a 1-week baseline followed by two active medication titration phases. Each phase of treatment was 1-4 weeks of titration with an additional stable dose week. The final dose was based on efficacy and adverse events for each patient. Efficacy measures included Clinical Global Impressions (CGI) and Conners' Parent and Teacher Rating Scales (CPRS and CTRS). The Clinical Assessment of Side Effects (CASE) scale assessed frequency of adverse events. Results: Of the 90 enrolled patients, aged 6.4-17.5 years, 79 (88%) completed the study. Stable daily doses were 32.0 and 32.5 mg for MLR and IR-MPH, respectively. All efficacy parameters were significantly improved from baseline. A total of 73.2% and 81.0% of patients on MLR and IR-MPH were rated as "much" or "very much improved" on the CGI. A total of 77.4% and 81.1% of patients were normalized on the CPRS-R and 78.9 and 90.4% of patients were normalized on the CTRS-R for MLR and IR-MPH, respectively. The mean CASE score was not different from baseline for either treatment.

Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Publishing Authors By Initials

M Weiss,L Hechtman,A Turgay,U Jain,D Quinn,TS Ahmed,T Yates,JL Reiz,GA Donnelly,Z Harsanyi,AC Darke,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of child and adolescent psychopharmacology

VOLUME: 17

Page Numbers: 675-88

Journal Abbreviation:

ISSN: 1044-5463

DAY: 5

MONTH: Nov

YEAR: 2007

Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9105358

Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.

AFFILIATION: Children's & Women's Health Centre of BC, Vancouver, British Columbia, Canada.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Child Adolesc Psychopharmaco

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder Related Publications

• A new HLA-B*15 variant - B*9507.
• A randomized, double-blind, crossover comparison of the efficacy and safety of oral controlled-release tramadol and placebo in patients with painful osteoarthritis.
• A typing system for the major histocompatibility complex class I chain related genes A and B using polymerase chain reaction with sequence-specific primers.
• Animal tissue culture with a synthetic medium.
• Cognitive and behavioral effects of multilayer-release methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder.
• Comparison of oxazepam, flurazepam and chloral hydrate as hypnotic sedatives in geriatric patients.
• Heredity as an etiological factor in homosexuality.
• Ilo-femoral venous thrombosis after operations on the hip. A prospective controlled trial using dextran 70.
• Immunological mechanisms in the pathogenesis of vinyl chloride disease.
• Injecting drug users and the Human Immunodeficiency Virus: what do we know?
• Methamphetamine and cardiovascular pathology: a review of the evidence.
• Once-daily multilayer-release methylphenidate in a double-blind, crossover comparison to immediate-release methylphenidate in children with attention-deficit/hyperactivity disorder.
• Once-daily, controlled-release tramadol and sustained-release diclofenac relieve chronic pain due to osteoarthritis: A randomized controlled trial.
• Serum ferritin, blood donation, iron stores and haemochromatosis.
• The measurement of outcome in opiate treatment evaluation studies.
• The use of benzodiazepines among injecting drug users.
• Truth is not always found in the laboratory.
• Tubercle bacilli in cerebrospinal fluid of dementia praecox.
• [Commentary] FROM THE CAN TO THE COFFIN: DEATHS AMONG RECENTLY RELEASED PRISONERS.